A novel next generation sequencing assay as an alternative to currently available methods for hepatitis C virus genotyping
- PMID: 29045810
- DOI: 10.1016/j.jviromet.2017.10.005
A novel next generation sequencing assay as an alternative to currently available methods for hepatitis C virus genotyping
Abstract
Chronic HCV infection is one of the leading causes of liver-related death and in many countries it is a primary reason for having a liver transplant. HCV genotype identification has long been used in the clinical practice, since different genotypes have different response rates and required different doses and durations of IFN/RBV treatment; moreover both the frequency and the pattern of resistance to different Direct-Acting Antivirals (DAAs) classes are subtype specific. Hence the necessity to make an accurate HCV subtyping becomes a fundamental tool to optimize current and future clinical management of HCV infected subjects. In the present study the performance of a next generation sequencing (NGS: based on the Ion Torrent Platform-Vela Sentosa SQ 301 sequencer) HCV genotyping assay has been evaluated. The current method targets a region of the NS5B gene and it is the unique NGS based market CE-IVD assay. As a comparative method a commercial method based on the detection via reverse hybridization of 5'UTR and core regions (Versant HCV Genotype 2.0 Assay, LiPA, Siemens) was selected. A total 207 plasma samples from HCV infected individuals were used. No selection was made for these samples that were submitted for routine HCV genotyping. The results show Vela NGS assay assigns major number of HCV subtypes with respect LiPA. Concerning genotype 1 and 3, the discrepancy of assigned subtypes for LiPA with respect to Vela NGS assay is not relevant (1.8% and 2%, respectively); in contrast, the difference of assigned subtypes for genotypes 2 and 4 is very high (96.6% and 100%, respectively). The resistance mutations data, except for 1a and 1b subtypes, remain scarce; the future relevant challenge will be to identify subtypes-specific drug resistance mutations, which are essential to create highly personalized therapeutic pathways.
Keywords: HCV genotyping; HCV subtype; Hepatitis-C; Ion torrent; NGS.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Full-genome next-generation sequencing of hepatitis C virus to assess the accuracy of genotyping by the commercial assay LiPA and the prevalence of resistance-associated substitutions in a Belgian cohort.J Clin Virol. 2022 Oct;155:105252. doi: 10.1016/j.jcv.2022.105252. Epub 2022 Aug 4. J Clin Virol. 2022. PMID: 35981443
-
High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods.J Clin Microbiol. 2015 Jan;53(1):219-26. doi: 10.1128/JCM.02093-14. Epub 2014 Nov 5. J Clin Microbiol. 2015. PMID: 25378574 Free PMC article.
-
Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6.J Clin Microbiol. 2016 Jul;54(7):1835-1841. doi: 10.1128/JCM.00238-16. Epub 2016 May 4. J Clin Microbiol. 2016. PMID: 27147726 Free PMC article. Clinical Trial.
-
Profile of the VERSANT HCV genotype 2.0 assay.Expert Rev Mol Diagn. 2018 Dec;18(12):995-1004. doi: 10.1080/14737159.2018.1541740. Epub 2018 Nov 2. Expert Rev Mol Diagn. 2018. PMID: 30372355 Review.
-
A review of historical landmarks and pioneering technologies for the diagnosis of Hepatitis C Virus (HCV).Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1289-1303. doi: 10.1007/s10096-025-05110-y. Epub 2025 Mar 22. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40119224 Review.
Cited by
-
Application of magnetic nanoparticles in nucleic acid detection.J Nanobiotechnology. 2020 Apr 21;18(1):62. doi: 10.1186/s12951-020-00613-6. J Nanobiotechnology. 2020. PMID: 32316985 Free PMC article. Review.
-
A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination.Sci Rep. 2018 Mar 8;8(1):4180. doi: 10.1038/s41598-018-22614-0. Sci Rep. 2018. PMID: 29520035 Free PMC article.
-
Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial.Infect Drug Resist. 2019 Apr 18;12:937-945. doi: 10.2147/IDR.S206938. eCollection 2019. Infect Drug Resist. 2019. PMID: 31114268 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials